From: Laparoscopic pancreaticoduodenectomy: are the best times coming?
Author | Study period (years) | Country | Study design | Number of patients LPD/OPD | Operation time, mean ± SD/median (range), (min) LPD/OPD | Length of stay, mean ± SD/median (range), (days) LPD/OPD | Estimated blood loss, mean ± SD/median (range), (ml) LPD/OPD | Pathology | Overall survival (month)/5-year survival rate |
---|---|---|---|---|---|---|---|---|---|
van Hilst et al. [24] | 2016–2017 | Dutch | PS,MC | 50/49 | 410 (252–481)/274 (212–317)* | 12 (7–21)/11 (7–24) | 300 (200–438)/450 (300–1000)* | PDAC, IPMN, ampullary tumor, CC, DC, NET, other | – |
Zhang et al. [17] | 2014–2016 | China | RS, SC | 202/213 | 301 ± 175/320 ± 91 | 12.97 ± 7.21/19.18 ± 7.14* | 194 ± 107/390 ± 301 | – | – |
Zimmerman et al. [28] | 2014–2015 | USA | RS, NSQIP | 280/6336 | 421 (331.5–499)/354 (277–437.5)* | 7 (6–12)/9 (7–13)* | – | – | – |
Chen et al. [27] | 2013–2017 | China | RS, SC | 47/55 | 410 ± 68/245 ± 70* | 13 ± 4/18 ± 5.5* | 210 ± 46/420 ± 50* | PDAC, IPMN, periampullary tumor, CC | – |
Poves et al. [25] | 2013–2017 | Spain | PS, SC | 32/29 | 486 (337–767)/365 (240–510)* | 13.5 (5–54)/17 (6–150)* | – | PDAC, IPMN, ampullary tumor, SPT, NET, other | – |
Palanivelu et al. [26] | 2013–2015 | India | PS, SC | 32/32 | 359 ± 14/320 ± 13 | 7 (5–52)/13 (6–30)* | 250 ± 22/401 ± 46* | Periampullary tumors | – |
Meng et al. [15] | 2010–2015 | China | PS, SC | 58/58 | 475.0 (420.0–546.3)/335.0 (275.0–405.0)* | 14.0 (11.0–17.3)/13.0 (11.0–20.0) | 200.0 (100.0–325.0)/220.0 (150.0–400.0) | Nonpancreatic periampullary adenocarcinomas | 45/48 |
Tan et al. [18] | 2009–2014 | China | RS, SC | 30/30 | 513.17 ± 56.13/371.67 ± 85.53* | 9.97 ± 3.74/11.87 ± 4.72* | – | Mainly periampullary adenocarcinoma | – |
Delitto et al. [19] | 2010–2014 | The USA | PS, SC | 52/50 | 361 (–)/360 (–) | 9.0 (–)/11.9 (–)* | 260 (–)/518 (–)* | Periampullary adenocarcinoma | 27.9/23.5 |
PDAC | 20.7/21.1 | ||||||||
Sharpe et al. [33] | 2010–2011 | The USA | RS, NCDB | 384/4037 | – | 10 ± 8.0/12 ± 9.7* | – | PDAC | – |
Kantor et al. [31] | 2010–2013 | The USA | RS, NCDB | 828/7385 | – | 10 ± 9/12 ± 9* | – | PDAC (stage I–II) | 20.7/20.9 |
Chapman et al. [20] | 2010–2013 | The USA | RS, MC | 248/1520 | – | 10 (7.0–15.0)/10 (7.0–15.5) | – | PDAC | 19.8/15.6# |
Langan et al. [35] | 2010–2013 | The USA | RS, SC | 28/25 | 355/347 | 7.10/9.44* | 336 (100–1400)/454 (100–1200) | PDAC, CC, other | – |
Croome et al. [21] | 2008–2013 | The USA | RS, SC | 108/214 | 379.4 ± 93.5/387.6 ± 91.8 | 6 (4–118)/9 (5–73) | 492.4 ± 519.3/866.7 ± 733.7* | PDAC | 25.3/21.8 |
Zureikat et al. [23] | 2008–2010 | The USA | RS, SC | 14/14 | 456 (334–583)/372.5 (290–628) | 8 (5–28)/8.5 (–) | 300 (150–1300)/400 (–) | – | – |
Song et al. [22] | 2007–2012 | South Korea | RS, SC | 97/198 | 480.4 ± 116.4/351.9 ± 83.3* | 14.1 ± 7.7/20 ± 10.7* | 592 ± 376/555 ± 462 | Benign or low-grade malignant tumors | – |
93/93 | 482.5 ± 117.6/347.9 ± 87.2* | 14.3 ± 7.8/19.2 ± 8.8 | 609 ± 375/570 ± 448 | PDAC and ampulla of Vater cancer | – | ||||
Asbun et al. [36] | 2005–2011 | The USA | RS, SC | 53/215 | 541 ± 88/401 ± 108 | 8 ± 3.2/12.4 ± 8.5 | 195 ± 136/1032 ± 1151 | PDAC, IPMN, other | – |
Hakeem et al. [34] | 2005–2009 | The UK | RS, SC | 12/12 | – | 14.9 ± 6.6/14.9 ± 5.7 | – | Periampullary adenocarcinoma, common bile duct tumors | 75%/50% |
Khaled et al. [29] | 2002–2015 | The UK | PS, SC | 15/15 | 470 (280-660)/310 (240-490)* | 9.0 (7–20)/15.4 (8–49)* | 300 (50-600)/620 (150–1200)* | Malignant lesions | 67%/53% |
Conrad et al. [30] | 2000–2010 | The USA | RS, SC | 40/25 | – | 23 (9–311)/28 (11–179) | – | PDAC | 35.5/29.6 |
Stauffer et al. [32] | 1995–2014 | The USA | RS, SC | 58/193 | 518 (313–761)/375 (159–681)* | 6 (4–68)/9 (4–71)* | 250 (50–8500)/600 (50–7800)* | PDAC | 32.07%/15.34% |
Lee et al. [16] | 1993–2017 | South Korea | RS,SC | 31/31 | 426.8 ± 98.58/355.03 ± 100.0* | 14.74 ± 5.40/23.81 ± 11.63* | 477.42 ± 374.80/800.00 ± 531.35* | Benign and borderline malignant Periampullary disease | – |